本帖最后由 老马 于 2013-3-13 13:43 编辑
' D5 ~5 i3 L( J5 `) Q9 F
) `1 X4 [ N9 [; z健择（吉西他滨）+顺铂+阿瓦斯汀
. K6 o2 a# B: O# G: p5 ?$ P6 _5 i Gemzar +Cisplatin + Avastin
' D. ~/ S- C, j/ c8 yhttp://annonc.oxfordjournals.org/content/21/9/1804.full5 @$ D7 L# ]% Y1 `/ g! m3 K
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) - ^$ ^$ I' _0 h6 G& i/ F" [" D
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
9 c, z" L' p0 Z( {) FResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ' y" d: Z, t+ S* T5 R8 s S
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 859)
+ x1 V3 P$ i1 |! i7 x
华为网盘附件：% X9 o7 e7 E! r1 ^$ S
【华为网盘】ava.JPG1 F4 H$ o2 M% Q2 U# W _
|
肺癌术后五年，脑膜转移治疗三年，伏
2020年7月右上胸腔镜下肺癌根治术，术后病理（右上肺叶）周围浸润性腺癌（腺泡亚型为
癌细胞都怕的维生素，有些肿瘤患者却
维生素可以说是病友们熟悉的陌生人。熟悉，是因为家里或多或少都会备一些；陌生，则是
高温来袭，西瓜、绿豆汤、雪糕这些“
进入6月，天气越发炎热，高温预警不断，不少朋友也在群里问小爱：
天气这么热，肿瘤
肺腺癌区域转移加脑转骨转ALK突变单
各位前辈，本人去年2022年9月确诊肺腺癌，伴区域转移、脑转、骨转、肌转，ALK突变，单
EGFR19+C797S和MET扩增+1230C，奥西
250123
病人是我妈妈，43年8月的，81周岁。
19年10月28日确诊，肺腺癌晚期，右上肺
显身卡
